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BACKGROUND
Mutations in RPE65 cause Leber’s congenital amaurosis, a progressive retinal de-
generative disease that severely impairs sight in children. Gene therapy can result 
in modest improvements in night vision, but knowledge of its efficacy in humans 
is limited.
METHODS
We performed a phase 1–2 open-label trial involving 12 participants to evaluate the 
safety and efficacy of gene therapy with a recombinant adeno-associated virus 2/2 
(rAAV2/2) vector carrying the RPE65 complementary DNA, and measured visual 
function over the course of 3 years. Four participants were administered a lower 
dose of the vector, and 8 were administered a higher dose. In a parallel study in 
dogs, we investigated the relationship among vector dose, visual function, and 
electroretinography (ERG) findings.
RESULTS
Improvements in retinal sensitivity were evident, to varying extents, in six partici-
pants for up to 3 years, peaking at 6 to 12 months after treatment and then declin-
ing. No associated improvement in retinal function was detected by means of ERG. 
Three participants had intraocular inflammation, and two had clinically signifi-
cant deterioration of visual acuity. The reduction in central retinal thickness varied 
among participants. In dogs, RPE65 gene therapy with the same vector at lower 
doses improved vision-guided behavior, but only higher doses resulted in improve-
ments in retinal function that were detectable with the use of ERG.
CONCLUSIONS
Gene therapy with rAAV2/2 RPE65 vector improved retinal sensitivity, albeit mod-
estly and temporarily. Comparison with the results obtained in the dog model 
indicates that there is a species difference in the amount of RPE65 required to 
drive the visual cycle and that the demand for RPE65 in affected persons was not 
met to the extent required for a durable, robust effect. (Funded by the National 
Institute for Health Research and others; ClinicalTrials.gov number, NCT00643747.)
A BS TR AC T
Long-Term Effect of Gene Therapy  
on Leber’s Congenital Amaurosis
J.W.B. Bainbridge, M.S. Mehat, V. Sundaram, S.J. Robbie, S.E. Barker, 
C. Ripamonti, A. Georgiadis, F.M. Mowat, S.G. Beattie, P.J. Gardner, 
K.L. Feathers, V.A. Luong, S. Yzer, K. Balaggan, A. Viswanathan, T.J.L. de Ravel, 
I. Casteels, G.E. Holder, N. Tyler, F.W. Fitzke, R.G. Weleber, M. Nardini, 
A.T. Moore, D.A. Thompson, S.M. Petersen-Jones, M. Michaelides, 
L.I. van den Born, A. Stockman, A.J. Smith, G. Rubin, and R.R. Ali
Original Article
The New England Journal of Medicine 
Downloaded from nejm.org at KU Leuven University Library on May 7, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 2
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Leber’s congenital amaurosis is a group of inherited, early-onset, severe reti-nal dystrophies that cause substantial sight 
impairment in childhood.1 One of the causes of 
this condition is mutations in the gene encoding 
RPE65 (retinal pigment epithelium–specific pro-
tein 65 kDa). The encoded retinoid isomerase 
converts all-trans retinyl esters to 11-cis retinal 
for the regeneration of visual pigment after ex-
posure to light. RPE65 deficiency causes photo-
receptor-cell dysfunction and impaired vision 
from birth. Severe dysfunction of rod photo-
receptor cells, which are wholly reliant on retinal 
pigment epithelium–derived RPE65, causes severe-
ly impaired night vision. The function of cone 
photoreceptor cells, which mediate vision in day-
light, is relatively preserved in childhood because 
cones have access to an alternative source of 
11-cis retinal.2 However, progressive degenera-
tion of both rod and cone photoreceptor cells, 
in association with local accumulation of toxic 
retinyl esters,3 results in severe sight impairment 
by early adulthood.
Augmentation of Rpe65 in animal models of 
Rpe65 deficiency can improve retinal and visual 
function, as assessed by means of electroretinog-
raphy (ERG) and observation of vision-guided 
behavior, respectively.4-6 We and others have pre-
viously reported that gene-augmentation therapy 
for RPE65 deficiency can improve aspects of 
sight in human participants.7-10 However, the 
magnitude and durability of benefit reported to 
date in humans do not match those observed in 
animal models.11
Species-specific differences in the outcomes 
of gene therapy are largely unexplained, but they 
may reflect differences in pathophysiological 
mechanisms, vector tropism, or both. The rate of 
retinal degeneration in humans is variable but, 
relative to life span, is typically higher than in 
mouse and dog models.11 Studies in animals have 
shown that improvements in function are corre-
lated with retinal thickness at the time of inter-
vention.11 The finding that the retinas even in 
older Rpe65-deficient dogs can respond with an 
improvement in function, despite local accumu-
lation of lipid metabolites and advanced photo-
receptor-cell degeneration,12 indicates that the 
window of opportunity for benefit is not restrict-
ed to early disease. However, the durability of 
the benefit from RPE65 gene augmentation de-
pends on protection against retinal degeneration, 
and in both mice and dogs, RPE65 gene augmen-
tation promotes the survival of photoreceptors 
only when it is administered early in the course 
of the disorder.13,14 In one study involving human 
participants, intervention between the ages of 11 
and 30 years failed to protect against degenera-
tion despite sustained improvements in retinal 
function.11 However, the optimal window of op-
portunity for intervention in humans has yet to 
be determined.
Here we report the 3-year results of a phase 
1–2 trial of gene therapy in humans with dis-
ease-causing mutations in RPE65. We also report 
the results of a parallel study in dogs to deter-
mine the relative demand for RPE65 protein and 
the effect of vector dose on retinal function.
Me thods
Trial Design and Oversight
We performed a phase 1–2 open-label trial in-
volving 12 participants to evaluate the safety 
and efficacy of gene therapy with a recombi-
nant adeno-associated virus 2/2 (rAAV2/2) vector, 
rAAV2/2.hRPE65p.hRPE65, carrying the RPE65 com-
plementary DNA (cDNA), administered at two 
dose levels. The study was approved by the U.K. 
Gene Therapy Advisory Committee, the Medicines 
and Healthcare Products Regulatory Agency, and 
the Moorfields Research Governance Committee 
and was conducted in compliance with Good 
Clinical Practice guidelines in accordance with 
the European Clinical Trials Directive (2001 
EU/20/EC) and the Declaration of Helsinki. Par-
ticipants or their guardians gave written in-
formed consent. The authors verified the data, 
made the decision to submit the manuscript for 
publication, and vouch for the completeness of 
the data, the accuracy of the analyses, and the 
fidelity of the study to the protocol, available 
with the full text of this article at NEJM.org.
Trial Participants
We included 12 participants (6 to 23 years of age) 
with early-onset, severe retinal dystrophy caused 
by mutations in RPE65 (Table 1). Their genotypes 
were confirmed at a National Health Service di-
agnostic laboratory. Residual enzyme function 
was estimated for the G40S and R91W muta-
tions15 and the Y368H mutation16 by means of 
prediction of protein structure. For each partici-
pant, the eye with the poorer visual acuity was 
selected as the study eye; the contralateral eye 
served as an untreated control.
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Intervention
The vector-manufacture process and surgical de-
livery technique have been described elsewhere.7 
To determine the effect of RPE65 gene supple-
mentation on foveal cones, we aimed to include 
the fovea within the subretinal vector bleb (i.e., 
the area of neurosensory retina that is elevated 
by the subretinal injection of vector suspension) 
in each participant. We administered the lower 
dose (1×1011 vector genomes) to the first four 
participants and the higher dose (1×1012 vector 
genomes) to the subsequent eight participants. 
We measured vector dissemination and systemic 
immune responses as described in the Supple-
mentary Appendix, available at NEJM.org.
Outcome Measures
We evaluated participants at baseline and at in-
tervals for 3 years after vector administration. 
We measured visual acuity, contrast sensitivity, 
Participant 
No. Age
RPE65 Mutation 
(% Residual 
Enzyme Function)†
Vector 
Dose‡
Visual Acuity 
at Baseline§
Peak Retinal 
Sensitivity on Dark-
Adapted Perimetry¶
Peak Retinal 
Sensitivity on 
Microperimetry
Vision-
Guided 
Ambulatory 
Navigation‖
Study 
Eye
Control 
Eye
Study 
Eye
Control 
Eye
Study 
Eye
Control 
Eye
yr vg log MAR dB-sr
1 23 Y368H (0.87) 
Y368H (0.87)
1×1011 1.16 0.88 0 0 0 0 −4
2 17 IVS1+5g→a (NA) 
G40S (1.65)
1×1011 1.52 1.62 0 0 0 0 −1
3 18 E6X (NA) 
D167Y (NA)
1×1011 0.76 0.50 54 2 1.4 0.5 0
4 11 K298fs (NA) 
Y368H (0.87)
1×1011 0.91 0.75 0 0 1.0 0 −1
5 23 Y368H (0.87) 
Y368H (0.87)
1×1012 0.36 0.31 26 8 0.8 0 8
6 17 Y368H (0.87) 
Y368H (0.87)
1×1012 0.68 0.53 46 7 1.5 0 2.5
7 10 IVS1+5g→a (NA) 
IVS12–2a→g (NA)
1×1012 0.44 0.46 0 0 0 0 0.5
8 10 R91W (5.08) 
R91W (5.08)
1×1012 0.69 0.64 20 0 0.3 0 5
9 6 IVS1+5g→a (NA) 
IVS1+5g→a (NA)
1×1012 0.82 0.89 0 0 0 NT NP
10 6 IVS1+5g→a (NA) 
Y368H (0.87)
1×1012 0.80 0.70 10 0 0 0 7
11 13 R124X (NA) 
F530fs (NA)
1×1012 0.63 0.55 0 0 0 0 −0.5
12 19 G40S (1.65) 
G40S (1.65)
1×1012 0.54 0.60 5 0 0.3 0 2.5
*  The term dB-sr denotes decibel–steradian units, MAR minimum angle of resolution, NA not applicable, NP the participant was not able to 
perform the test, NT the participant was not tested, and vg vector genomes.
†  Residual enzyme function was estimated for the G40S, R91W, and Y368H mutations by means of prediction of protein structure. 
Predictions are unavailable for the other mutations. Residual enzyme function is expressed as a percentage of normal enzyme function.
‡  The injection volume was 0.9 ml in Participants 1 and 9 and 1 ml in all other participants; vector administration involved the fovea in all 
participants except Participants 9 and 11.
§  Values are the mean of three separate assessments at baseline.
¶  Values are the number of locations with significant positive slope (P<0.05), as compared with the baseline measurement, as evaluated with 
the use of pointwise linear regression.
‖  Values are the improvement in performance at an ambient illumination of 4 lux 6 months after vector administration, assessed as the differ-
ence in the number of errors made by the participant when the study eye and the control eye were used independently while navigating a course.
Table 1. Participant Characteristics, Dosing, and Selected Outcomes.*
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color vision, and spectral sensitivities. For the in-
vestigation of visual fields, we used microperim-
etry, Goldmann kinetic perimetry, and photopic 
and scotopic (dark-adapted) automated static 
perimetry; we also assessed vision-guided ambu-
latory navigation and performed color fundus 
photography, autofluorescence imaging, optical 
coherence tomography (OCT), and ERG. The 
primary safety outcome was the incidence of a 
grade 3 adverse event at 3 years, defined as either 
the loss of visual acuity by 15 or more letters on 
the Early Treatment of Diabetic Retinopathy 
Study (ETDRS) chart or severe unresponsive intra-
ocular inflammation.
Statistical Analysis
The outcomes for efficacy were descriptive in 
nature and were defined as any improvement in 
visual function greater than the test–retest vari-
ability for any assessment, determined by means 
of one-way analysis of variance with the use of 
multiple baseline measurements.17 A detailed 
description of the methods used in the dose–
response study in the dog model, as well as the 
statistical analysis of the results in that model, 
can be found in the Supplementary Appendix.
R esult s
Vector Administration
The bleb of subretinal vector extended to include 
the fovea in all eyes except two (in Participants 
9 and 11). We observed no intraoperative adverse 
events. Subretinal vector was fully absorbed with-
in 24 to 48 hours, as indicated by findings on 
OCT. Lacrimal fluid samples were weakly posi-
tive for vector DNA sequences at 1 day after 
surgery, but not at 30 days, in one participant 
(Participant 4) who was given the lower dose of 
vector and in two participants (Participants 7 and 
10) who were given the higher dose. Vector DNA 
was not detected in the participants’ peripheral 
blood, saliva, or semen (semen was analyzed in 
one participant).
Adverse Events
The ocular adverse events we observed included 
mild or transient intraocular inflammation in 
three participants who received the higher dose 
(Table S1 in the Supplementary Appendix). Mac-
ular thinning and a decline in visual acuity were 
also evident after subfoveal vector administra-
tion. The systemic adverse events we observed 
included those known to be associated with oral 
glucocorticoids.
Retinal Sensitivity and Vision-Guided 
Ambulatory Navigation
The outcomes for efficacy were primarily descrip-
tive in nature. Improvements in retinal sensitivity 
were evident in the study eyes of six participants 
(Participants 3, 5, 6, 8, 10, and 12) on dark-
adapted perimetry (Fig. 1) and in five of these 
participants (Participants 3, 5, 6, 8, and 12) on 
microperimetry (Fig. S1 and S2 in the Supple-
mentary Appendix). For the first 4 months after 
vector administration, maximal improvement of 
rod function after vector administration was evi-
dent on dark-adapted perimetry only after extend-
ed dark adaptation (Fig. S3 in the Supplementary 
Appendix), with retinal sensitivity improving pro-
gressively for up to 4 hours during dark adapta-
tion. Five of these participants (Participants 3, 5, 
6, 8, and 10) reported subjective improvements 
in night vision, with three of them (Participants 
5, 8, and 10) showing improvements in vision-
guided ambulatory navigation (Fig. 2). One par-
ticipant (Participant 4) reported subjectively im-
proved night vision but had no consistent 
measurable improvement in retinal sensitivity or 
navigation.
Spectral Sensitivity
Measurement of spectral sensitivities at a fixed 
location in the superior retina after administra-
tion of the higher dose confirmed that two 
participants (5 and 6) had substantial improve-
ments (10 to 100 times as high) in rod sensitiv-
ity that peaked at 12 months after treatment and 
subsequently declined (Fig. S4A in the Supple-
mentary Appendix). For Participant 6, improve-
ments were proportionately greater at 500 nm 
than at 600 nm, which indicated recovery of rod 
function. For Participant 5, similar improvements 
at 500 and 600 nm indicated an improvement in 
cone function. After rod bleaching (i.e., depigmen-
tation of photopigment as a result of exposure 
to bright light), spectral sensitivities collapsed to 
become cone-like during the cone plateau and 
indicated improved cone photoreceptor-cell func-
tion in one participant (Participant 5) (Fig. S4B 
in the Supplementary Appendix). Other partici-
pants had only modest improvements in cone 
flicker sensitivity, and we found no evidence of 
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improved cone function on dark-adapted perim-
etry with a red light stimulus.
Visual Acuity
The participants had a wide range of visual acu-
ities at baseline (Fig. S5 in the Supplementary 
Appendix). In one participant (Participant 11), 
an apparent improvement in visual acuity in the 
study eye was accompanied by a similar im-
provement in the contralateral untreated eye; 
with this exception, no consistent improvement 
in visual acuity was evident. A decline in visual 
acuity by more than 15 letters on the ETDRS 
chart was observed in two participants (Partici-
pants 3 and 7), and a more modest but sustained 
decline in acuity only in the study eye was appar-
ent in one additional participant (Participant 12). 
In two of the participants with a decline in vi-
Figure 2. Vision-Guided Ambulatory Navigation.
The participants’ abilities to navigate a course at a range of illuminances 6 months after vector administration were assessed by mea-
surement of the number of navigational errors made when the study eye and control contralateral eye were used independently. The 
dark blue bars indicate, for each participant tested, the difference between the study eye and control eye in the number of errors made. 
Bars that extend upward from 0 indicate fewer errors for the study eye than for the control eye for each participant. The gray-shaded areas 
indicate the test–retest variability, determined by one-way analysis of variance with the use of multiple baseline measurements. The four 
rows of data are results for each of the lighting conditions; only Participants 5 through 12 were tested at 2 lux. Participants 5, 8, and 10 
had better performance with their study eyes at lower illuminances. Participants 1 and 9 had better performance with their untreated con-
trol eye at the highest illuminance. NP denotes that the participant was not able to perform the test, and NT denotes that the participant 
was not tested.
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sual acuity (Participants 7 and 12), the decline 
was associated with a subjective deterioration of 
vision.
ERG
Rod photoreceptor-mediated responses measured 
with the use of ERG were undetectable at base-
line, and we measured no significant sustained 
change in rod or cone responses in any partici-
pant; participants who had very-low-amplitude 
residual ERG findings retained the same level of 
function.
Inflammatory and Immune Responses
Either intraocular inflammation or immune re-
sponses occurred in five of the eight partici-
pants who received the higher dose (Partici-
pants 5 through 12) but in none of the four 
participants who received the lower dose (Par-
ticipants 1 through 4). These responses ap-
peared nondeleterious in all participants except 
Participant 7, in whom an episode of mild ante-
rior uveitis was followed by focal pigmentary 
changes at the macula (Fig. S6 in the Supple-
mentary Appendix) and a persistent reduction in 
visual acuity by 15 letters on the ETDRS chart 
(Fig. S5 in the Supplementary Appendix). At 
week 4, this participant had evidence of an in-
crease in neutralizing AAV2 antibodies and a 
marginal increase in circulating T cells with 
reactivity to AAV2, as determined with the use 
of an enzyme-linked immunosorbent spot 
(ELISpot) assay, but no elevation in the titer of 
antibodies against RPE65 (Table S2 in the Sup-
plementary Appendix). Two participants (Par-
ticipants 8 and 9) had asymptomatic episodes of 
posterior intraocular inflammation in the study 
eye (Fig. S6 in the Supplementary Appendix); in 
one participant (Participant 8), this was associ-
ated with a temporary attenuation of the im-
provements in retinal sensitivity (Fig. 1, and Fig. 
S1 in the Supplementary Appendix). Intraocular 
inflammation in Participant 9 was associated 
with transiently increased circulating neutral-
izing antibodies to AAV2 (Table S2 in the Sup-
plementary Appendix), but no adverse effect on 
visual function was evident. Fluorescein angiog-
raphy and fundus autofluorescence imaging at 
12 months after therapy showed no significant 
change from baseline in any participant (data 
not shown).
Retinal Thickness
Of the 10 eyes in which subretinal vector admin-
istration involved the fovea (i.e., in all partici-
pants except 9 and 11), 6 had a sustained reduc-
tion in macular thickness (Participants 4 through 
8 and 12) (Fig. S7A in the Supplementary Appen-
dix). Macular thinning was typically apparent 
within 3 months and subsequently was relatively 
stable. Associated thinning of the photoreceptor-
cell (outer nuclear) layer was evident, with vari-
able disruption of the photoreceptor ellipsoid 
(inner segment) zone (Fig. S7B in the Supple-
mentary Appendix).
Dose–Response Relationship in Rpe65-
Deficient Dogs
To investigate the differences in the responses to 
gene augmentation between dogs and humans 
with RPE65 deficiency, we estimated the normal 
demand for RPE65 in each species by measuring 
the endogenous expression of the protein and 
performed a dose–response study of Rpe65 gene 
augmentation in dogs. The expression of RPE65 
messenger RNA in the human eye was 2.5 times 
as high as that in the dog eye (P = 0.02), which 
suggests that the human eye has a correspond-
ingly higher requirement for RPE65 protein. The 
highest dose of rAAV2/2.hRPE65p.hRPE65 vector 
in dogs corresponded to the greatest amounts 
of RPE65 immunostaining (Fig. 3A), recombi-
nant RPE65 protein (Fig. 3B), and 11-cis retinal 
(Fig. 3C), as well as the highest ERG response 
(Fig. 3D). The effect of gene augmentation on 
vision in dogs was strongly correlated with vec-
tor dose (R = 0.58, P<0.001) (Fig. 3D). Dogs ad-
ministered the lower dose (4×109 vector genomes) 
had significantly better vision than untreated 
dogs (P = 0.02 by Student’s t-test) but no signifi-
cant measurable improvement in ERG response.
Discussion
In 2008, we reported the preliminary results of this 
trial, which showed increased retinal sensitivity 
in 1 of 3 participants after intraocular administra-
tion of rAAV2/2.hRPE65p.hRPE65.7 Here, we report 
the outcomes in all 12 participants after 3 years. 
The magnitude of improved sensitivity within the 
treated area and the absence of an improvement 
of the same magnitude in the untreated contra-
lateral eye provide evidence that such improve-
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ments are the consequence of RPE65 supplemen-
tation. Improved retinal sensitivity was apparent 
in a greater proportion of participants adminis-
tered the higher dose (5 of 8 participants) than 
of those administered the lower dose (1 of 4 par-
ticipants), indicating a possible dose–response 
effect; however, the number of participants in each 
group was small, and therefore the difference in 
proportions is suggestive rather than definitive. 
Even at the higher dose, the level of improve-
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ment in retinal sensitivity differed widely among 
participants, and no improvement was of a mag-
nitude that could be detected by means of ERG. 
These observations are consistent with those of 
other investigators.18,19 In contrast, the responses 
after the same intervention in animal models of 
Rpe65 deficiency were predictably robust.
In common with the findings of Jacobson et 
al.,19 but in contrast to those of Maguire et al.,20 
we identified no clear correlation between re-
sponse and the age of the participant. In fact, 
the greatest improvements were evident in older 
participants (17, 18, and 23 years of age), and 
contrary to expectation, improvements in retinal 
sensitivity were of lower magnitude in younger 
participants who had the greatest preservation 
of retinal structure. The weaker effect in younger 
participants is unexplained but, in the context of 
a relatively well-preserved population of photo-
receptor cells, the provision of a limited supply 
of 11-cis retinal may fail to meet a threshold re-
quired by individual cells for improved function. 
The majority of participants had at least one 
missense mutation known to mediate residual 
isomerase activity (Table 1), but we identified no 
clear correlation between participants’ genotypes 
and their response to the intervention.
Maximal retinal sensitivity was reached only 
after a substantially extended period of dark 
adaptation. This finding is consistent with a 
previous report of incomplete restoration of dark 
adaptation,21 indicating that the kinetics of the 
reconstituted retinoid cycle can remain abnor-
mally slow after RPE65 gene supplementation. 
The level of RPE65 protein expressed may be in-
sufficient to support normal provision of 11-cis 
retinal. Cideciyan et al.,21 citing evidence that 
RPE65 haploinsufficiency may not delay dark 
adaptation,22 suggested an alternative explanation, 
in which diffusion or transport of 11-cis retinal 
to photoreceptor cells is limited by an undefined 
“resistive barrier.” They suggested that such a 
barrier may be enhanced in RPE65 deficiency by 
the accumulation of all-trans-retinyl esters, lipid 
droplets, or disorganized rod outer segments3 or 
by retinal detachment that is induced temporar-
ily by vector delivery.23 However, our finding that 
the improvements in retinal sensitivity were of 
greater magnitude in older participants than in 
younger participants suggests that the limitation 
results not from any progressively resistant bar-
rier to diffusion but rather from limited enzy-
matic activity that fails to meet the demand of 
the surviving populations of photoreceptor cells.
Although RPE65 insufficiency typically causes 
severe rod photoreceptor-cell dysfunction, cone-
mediated vision is relatively well preserved in the 
early stages. Whereas rod photoreceptor-cell func-
tion is critically dependent on the provision of 
11-cis retinal by the retinal pigment epithelium, 
cone photoreceptor cells have an alternative 
source of the enzyme.2,24,25 Despite vector having 
been delivered to the fovea in the majority of 
participants, there was no improvement in foveal 
function, a finding consistent with results of a 
previous study.19 We identified improved extra-
foveal cone function in only one participant. 
Other investigators have reported an improve-
ment in the function of extrafoveal cone photo-
receptor cells, as indicated by variably improved 
visual acuity in extrafoveal-fixating eyes19 and at 
very low levels of visual acuity.20 The question of 
why RPE65 gene supplementation improves the 
function of extrafoveal cones but not that of fo-
veal cones remains unresolved.
An improvement in retinal sensitivity was 
evident within 1 to 2 months after vector admin-
istration, with progressive improvement for 6 to 
12 months. The sensitivity subsequently declined, 
although the maintenance of improvement above 
preintervention levels was still evident after 3 years 
in two participants (5 and 6). These findings are 
consistent with those of other studies, in which 
progressive retinal thinning11 and a progressive 
Figure 3 (facing page). Dose-Dependent Responses  
to Gene-Augmentation Therapy in Dogs.
Panel A shows the results of an immunohistochemical 
analysis demonstrating levels of RPE65 (in red) after 
administration of the indicated doses of vector (sub-
panels a–d). RPE65 signals are similar to wild-type levels 
(subpanel e) only at the highest dose. No signal is de-
tected in negative control samples without primary anti-
body (subpanel f). Autofluorescent signal (in green) in 
the subretinal space, shown in subpanels on the left, 
has been removed in the subpanels on the right to facili-
tate visualization of RPE65. DAPI denotes 4′,6-diamidino-
2-phenylindole, and GAPDH glyceraldehyde 3-phosphate 
dehydrogenase. Panel B shows the results of a Western-
blot analysis indicating levels of recombinant RPE65 
that are appreciable but lower than wild-type levels at 
the highest dose of injected vector. Panel C shows that 
the highest level of 11-cis retinal production corresponds 
to the highest dose of vector. The term vg denotes vec-
tor genomes. In Panel D, electroretinographic findings 
(left graph) show substantial restoration of the b-wave 
only at the highest dose of vector, whereas vision-guided 
behavior (right graph) shows dose dependency, with im-
proved function evident even at lower doses of vector.
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decline in function from the peak improve-
ment11,26 suggest ongoing retinal degeneration 
despite improved function in surviving cells.
In Rpe65-deficient mice and dogs, intervention 
with RPE65 gene supplementation before substan-
tial degeneration confers improvements in retinal 
function of a magnitude measurable by means of 
ERG and can protect against progressive degen-
eration.13,14 In trials involving humans to date, al-
though RPE65 gene supplementation can improve 
retinal function and there is some evidence of a 
dose response, neither the magnitude of im-
provement nor its durability has matched that 
observed in animal models. This disparity in re-
sponse between species may reflect differences in 
both the extent of established retinal degenera-
tion at the point of intervention and the ability 
to meet cellular requirements for RPE65. In animal 
models, the effect that Rpe65 gene augmentation 
has on protection against degeneration is highly 
dependent on the timing of intervention,11,13,14 
and because the onset of retinal degeneration, 
relative to life span, is earlier in humans than in 
mice and dogs, even earlier intervention is likely 
to be required for the most durable benefit in 
humans. In Rpe65-deficient dogs, we found that 
the effect of RPE65 gene supplementation is high-
ly dose-dependent, with a particularly steep dose–
response curve between doses of 1×1011 and 
2×1010 vector genomes. Although lower doses 
resulted in improvements in visual behavior, the 
effect was insufficient to generate measurable 
responses on ERG, and only higher doses have 
been associated with protection against progres-
sive degeneration.14 We also found that RPE65 
expression in humans is greater than that in 
dogs, which suggests that the demand for 
RPE65 in the human is higher. Taken together, 
these findings suggest that more efficient deliv-
ery of RPE65 at an appropriately early point in 
disease progression will have a greater effect on 
retinal function and will better protect against 
progressive degeneration.
Instances of intraocular inflammation and 
immune responses to AAV2 point to dose-limit-
ing toxic effects at the higher dose and suggest 
that the provision of RPE65 would be more safely 
enhanced by improvement of the efficiency of 
the vector construct rather than by administra-
tion of a higher dose of vector genomes. We also 
measured a reduction in central macular thick-
ness after subfoveal delivery of the vector. This 
finding is consistent with that in a previous 
study19 and is most likely a direct consequence of 
temporary detachment of the neurosensory retina. 
Although an adverse effect of retinal detachment 
on macular function is predictable,27 we consid-
ered that the risk of harm to foveal function 
from temporary detachment might be modest, 
as compared with the potential for benefit from 
the restoration of retinoid cycling. However, given 
the lack of evidence of benefit to foveal cone 
photoreceptor cells to date, delivery techniques 
should be considered that minimize the height 
and duration of any foveal detachment, possibly 
through the use of multiple injections. Careful 
attention should also be given to the extent of 
retinal area targeted; evidence that non–cell-
autonomous mechanisms can contribute to reti-
nal cell death28,29 suggests that widespread ad-
ministration to viable retina may help promote 
increased protection against degeneration.
Our results provide further evidence for im-
proved rod-photoreceptor function in response 
to AAV2-mediated RPE65 gene supplementation. 
In dogs, substantial improvements in retinal func-
tion were measurable by means of ERG and 
could protect against degeneration, but they were 
highly dose-dependent. In humans, the improve-
ments in retinal sensitivity were modest even in 
participants with relatively mild retinal degenera-
tion and failed to protect against ongoing degen-
eration. We conclude that gene therapy with an 
rAAV2/2 vector carrying the RPE65 cDNA led to 
temporary, variable, and incomplete restoration 
of retinal function in humans, which partly re-
flects a persistent unmet demand for RPE65.
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